---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-24-000060"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:40:05.455695+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibrx Biosciences Q3 net loss $43.9M ($2.84/shr); cash $196.3M; trial readouts in next 12 months

## Summary
- Cash and cash equivalents $196.3M as of Sep 30, 2024, down from $226.9M at June 30, 2024.
- Net loss of $43.9M ($2.84 per share) vs $51.8M ($4.39 per share) in Q3 2023.
- R&D expense $38.9M, up slightly from $38.1M, driven by expansion of Phase 2 trial for ozekibart (INBRX-109) and INBRX-106 trials.
- No outstanding third-party debt post-spin-off; other income of $2.9M from interest on cash balances.
- Company expects data readouts for its two ongoing clinical programs within the next 12 months.

## SEC filing metadata
- accession: 0002007919-24-000060
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000060/0002007919-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000060/inhibrx-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-24-000060
- JSON: https://secwatch.observer/filing/0002007919-24-000060.json
- Plain text: https://secwatch.observer/filing/0002007919-24-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.